Prior to establishing Tellus BioVentures, a lifesciences investment fund, Mr. Moulder co-founded TESARO and served as Chief Executive Officer and Director until its acquisition by GlaxoSmithKline. He previously served as President and Chief Executive Officer of Abraxis BioScience. Prior to Abraxis, he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and Chief Executive Officer. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began his career as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.
Mr. Moulder is a Temple University Trustee and a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. He serves on the Board of Directors for Zai Lab, Helsinn Group and Trevena, and for the Tellus BioVentures portfolio companies: Aegle Therapeutics, Interius BioTherapeutics, Navrogen, Praeventix, TamuroBio, Vittoria and Zenas BioPharma (as Executive Chairman). Mr. Moulder received a Pharmacy degree from Temple University and an M.B.A from The University of Chicago Booth School of Business.
Dr. Violin co-founded Dianthus in July 2019 and has served on the Board of Directors since. He was the President and Chief Executive Officer of Viridian Therapeutics, Inc. (NASDAQ: VRDN), which he also co-founded, and is an accomplished scientist and experienced leader in drug discovery and development, and in scientific platform development. He previously served as founding Chief Executive Officer of Quellis Biosciences. Prior to that, Dr. Violin co-founded and helped lead Trevena Inc. from discovery research through clinical development and NDA submission, including multiple rounds of venture and public financing.
Dr. Violin holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business, and a B.S. in Chemical Pharmacology from Duke University. He also serves on the boards of directors of Astria Therapeutics.